Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 13/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5346288 | 0.78 | PDE10A (0.38) | PDE10AALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL5347636 | 0.76 | FYN (0.38) | ALDH1A1MEN1KMT2ASMARCA2SMARCA4 | |
| SCHEMBL5354327 | 0.73 | NPC1 (0.57) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL5359975 | 0.72 | SMARCA2 (0.40) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL2900828 | 0.72 | CHRNA7 (0.37) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL5353727 | 0.72 | SMARCA2 (0.40) | ALDH1A1SMARCA2SMARCA4PBRM1NPC1 | |
| SCHEMBL5366414 | 0.71 | CHRM4 (0.35) | ALDH1A1KDM4EMEN1KMT2ASMARCA2 | |
| Hydrochloric Acid SCHEMBL2900298 | 0.71 | CHRNA7 (0.39) | ALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL5346283 | 0.71 | KDM4E (0.39) | ALDH1A1KDM4EHSD17B10SMARCA2SMARCA4 | |
| SCHEMBL6192934 | 0.69 | NPC1 (0.57) | ALDH1A1KDM4EMEN1KMT2AHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | claimed |
| US-7223753-B2 | Diazabicyclic biaryl derivatives | NEUROSEARCH A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | disclosed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | CHRNA6, CHRNA3, CHRNA2 | PDE10A 299/4885ALDH1A1 1023/4885KDM4E 2840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.